Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158516 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kyle L O'Donnell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilt…. Hauptthemen laut MEDLINE: Viral Vaccines, Marburgvirus, Marburg Virus Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Program, NIAID, NIH.
Abstract (Originalsprache)
Marburg virus (MARV), a filovirus, was first identified in 1967 in Marburg, Germany, and Belgrade, former Yugoslavia. Since then, MARV has caused sporadic outbreaks of human disease with high case fatality rates in parts of Africa, with the largest outbreak occurring in 2004/05 in Angola. From 2021 to 2023, MARV outbreaks occurred in Guinea, Ghana, New Guinea, and Tanzania, emphasizing the expansion of its endemic area into new geographical regions. There are currently no approved vaccines or therapeutics targeting MARV, but several vaccine candidates have shown promise in preclinical studies. We compared three vaccine platforms simultaneously by vaccinating hamsters with either a single dose of an adenovirus-based (ChAdOx-1 MARV) vaccine, an alphavirus replicon-based RNA (LION-MARV) vaccine, or a recombinant vesicular stomatitis virus-based (VSV-MARV) vaccine, all expressing the MARV glycoprotein as the antigen. Lethal challenge with hamster-adapted MARV 4 weeks after vaccination resulted in uniform protection of the VSV-MARV and LION-MARV groups and 83% of the ChAdOx-1 MARV group. Assessment of the antigen-specific humoral response and its functionality revealed vaccine-platform-dependent differences, particularly in the Fc effector functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
- Public Health Vaccines Inc., Cambridge, MA 02412, USA.
- HDT Bio, Seattle, WA 98102, USA.
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 7BN, UK.
ORCID-Profile: Hanna Anhalt, Joan Fusco, Jesse H Erasmus, Andrea Marzi
Förderung
- Intramural Research Program, NIAID, NIH
Zitieren
APA
O'Donnell, K. L., Henderson, C. W., Anhalt, H., Fusco, J., Erasmus, J. H., Lambe, T., & Marzi, A. (2024). Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158516
Vancouver
O'Donnell KL, Henderson CW, Anhalt H, Fusco J, Erasmus JH, Lambe T, et al. Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158516
BibTeX
@article{ODonnell2024,
author = {O'Donnell, Kyle L and Henderson, Corey W and Anhalt, Hanna and Fusco, Joan and Erasmus, Jesse H and Lambe, Teresa and Marzi, Andrea},
title = {Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158516}
}
EUVIMED